Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Wisconsin Brain Donor Program (WBDP)

This study is enrolling participants by invitation only.
Sponsor:
Collaborator:
Thomas Montine, M.D. University of Washington
Information provided by (Responsible Party):
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT00585572
First received: December 26, 2007
Last updated: October 22, 2014
Last verified: October 2014
  Purpose

The Wisconsin Brain Donor Program (WBDP) stores brain and other tissues/samples (e.g. blood and CSF) from deceased individuals who have participated in longitudinal research studies, as well as other select participants. These individuals have donated their tissues in order to aid scientific research. Through the collection of central and peripheral nervous tissues as well as (in select cases) skeletal muscle tissue, the WBDP strives to advance the knowledge of diseases of memory disorders, such as Alzheimer's Disease. Brain donations are needed from healthy individuals, as well as those affected by diseases of the nervous system.


Condition
Alzheimer's Disease
Mild Cognitive Impairment

Study Type: Observational
Official Title: University of Wisconsin-Madison: Wisconsin Brain Donor Program (WBDP)

Resource links provided by NLM:


Further study details as provided by University of Wisconsin, Madison:

Biospecimen Retention:   Samples Without DNA

Brain tissue, blood, cerebrospinal fluid, spinal cord, peripheral nerves, and skeletal muscles, central/peripheral nervous tissue, as well as skeletal muscle tissue.


Estimated Enrollment: 500
Study Start Date: March 2007
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Detailed Description:

The WBDP strives to provide well-characterized tissues/samples to researchers. The WBDP is aligned with the longitudinal research study of the Alzheimer's Disease Research Center (ADRC) in Madison, Wisconsin as well as other studies associated with the ADRC.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Participants agree to autopsy and brain/tissue/sample donation for research purposes only.

Criteria

Individuals enrolled in the longitudinal study of the Alzheimer's Disease Research Center (ADRC), additional studies affiliated with the ADRC, or select additional donors are invited to participate.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00585572

Locations
United States, Wisconsin
University of Wisconsin Madison
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
University of Wisconsin, Madison
Thomas Montine, M.D. University of Washington
Investigators
Principal Investigator: Shahriar Salamat, MD PHD University of Wisconsin, Madison
  More Information

No publications provided

Responsible Party: University of Wisconsin, Madison
ClinicalTrials.gov Identifier: NCT00585572     History of Changes
Other Study ID Numbers: H-2010-0037, H-2010-0037
Study First Received: December 26, 2007
Last Updated: October 22, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by University of Wisconsin, Madison:
Normal Tissues/Brains
Alzheimer
Motor Neuron Disease
Dementia
Healthy Control Volunteers
Populations At Risk
MCI

Additional relevant MeSH terms:
Alzheimer Disease
Cognition Disorders
Mild Cognitive Impairment
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Dementia
Mental Disorders
Nervous System Diseases
Neurodegenerative Diseases
Tauopathies

ClinicalTrials.gov processed this record on November 25, 2014